Physician profile

Mark Godish

Pulmonary Disease · Oklahoma City, OK

NPI 1689632937

$10,709.68

in general payments reported to CMS, 2019-2025

50 companies · $2,155 in 2025

The $2,155 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$5,655.13
Education$106.18

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Insmed, INC. $1,373.33 2019-2025 Arikayce, Brinsupri
Glaxosmithkline, LLC. $1,216.49 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $1,018.03 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Astrazeneca Pharmaceuticals LP $943.75 2019-2025 Fasenra, Tezspire, Breztri
Genzyme Corporation $808.28 2019-2025
Baxter Healthcare $600.41 2022-2025 Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System
Fisher & Paykel Healthcare INC $468.28 2022-2025 Fisher & Paykel Healthcare
Novartis Pharmaceuticals Corporation $378.11 2019-2025
Inspire Medical Systems, INC. $358.59 2023-2025 Inspire
Inogen, INC. $289.81 2022-2025 Inogen One G5 Oxygen Concentrator - Bluetooth
Genentech USA, INC. $229.20 2019-2024 Xolair
Actelion Pharmaceuticals US, INC. $223.86 2019-2025 Uptravi
Amgen INC. $200.57 2021-2025 Tezspire
Sunovion Pharmaceuticals INC. $193.39 2019
Allergan, INC. $180.82 2019-2020
Show all 50 companies
CompanyGeneral paymentsYearsTop products
Regeneron Healthcare Solutions, INC. $170.49 2020-2025 Dupixent
Pfizer INC. $148.35 2019-2022
Sanofi-Aventis U.S. LLC $140.34 2020-2024
Mallinckrodt Hospital Products INC. $135.06 2021-2022
Gilead Sciences, INC. $115.04 2021-2023
United Therapeutics Corporation $114.82 2019-2025 Tyvaso, Tyvaso
Takeda Pharmaceuticals U.S.A., INC. $110.86 2020-2024 Glassia
Merck Sharp & Dohme LLC $110.37 2019-2024 Winrevair
Axsome Therapeutics, INC. $107.44 2022-2025 Sunosi
Intuitive Surgical, INC. $105.85 2025
Jazz Pharmaceuticals INC. $96.62 2021-2025
Mylan Specialty L.P. $81.46 2019-2024 Yupelri
Harmony Biosciences LLC $69.70 2022-2025 Wakix
Alexion Pharmaceuticals, INC. $68.12 2019-2024 Ultomiris
Janssen Pharmaceuticals, INC $64.94 2021-2022
E.R. Squibb & Sons, L.L.C. $64.14 2020-2022
Vyera Pharmaceuticals, LLC $56.98 2020-2021
Abbvie INC. $51.90 2024-2025
Ani Pharmaceuticals, INC. $49.66 2022-2024 Purified Cortrophin Gel
Mayne Pharma Commercial LLC $39.72 2020
Philips North America LLC $33.44 2019-2025 Vest Therapy Und
Pulmonx Corporation $32.37 2025 Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter
Circassia INC. $32.19 2020
Masimo Corporation $29.08 2024
Paratek Pharmaceuticals, INC. $23.71 2025 Nuzyra
Avadel Cns Pharmaceuticals, LLC $23.44 2025 Lumryz
Boston Scientific Corporation $21.50 2019
Lilly USA, LLC $20.89 2025 Zepbound
La Jolla Pharmaceutical Company $18.52 2020
Arbor Pharmaceuticals, INC. $16.33 2020
Inari Medical, INC. $16.04 2023 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Advanced Respiratory, INC $15.10 2019
Teva Pharmaceuticals USA, INC. $14.31 2022
Phadia US INC. $14.29 2024 Immunocap
Verona Pharma, INC. $13.69 2025 Ohtuvayre

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Godish

$10,709.68

in general payments reported 2019-2025

Years
2019-2025
Top company
Insmed, INC.
Context
The $2,155 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/257450/mark-godish

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.